Community Programs, Product Recalls, Quarterly Reports, Product Launches, and Study Results - Research Report on DaVita, Novo Nordisk, Cynosure, Hospira, and Celsion Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 4, 2013 NEW YORK, November 4, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting DaVita HealthCare Partners Inc. (NYSE: DVA), Novo Nordisk A/S (NYSE: NVO), Cynosure, Inc. (NASDAQ: CYNO), Hospira Inc. (NYSE: HSP), and Celsion Corp. (NASDAQ: CLSN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. DaVita HealthCare Partners Inc. Research Report On October 15, 2013, DaVita HealthCare Partners Inc. (DaVita) and a leading provider of kidney care services announced that the seventh annual Tour DaVita® raised $1 million for The Kidney TRUST, a 501(c)(3) independent nonprofit organization that seeks to reduce the progression of chronic kidney disease through a no-cost, rapid screening in non-medical settings. Gloria Upchurch, Program Manager of The Kidney TRUST, commented, "The funds from this year's Tour DaVita will go a long way in supporting our mission." Upchurch added, "We will be able to continue helping communities around the country better understand their kidney health, including kidney disease risk factors." The Full Research Report on DaVita HealthCare Partners Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5986_DVA] -- Novo Nordisk A/SResearch Report On October 25, 2013, Novo Nordisk A/S (Novo Nordisk) announced the recall of certain batches of its prefilled insulin product NovoMix30 FlexPen in Austria, Belgium, Czech Republic, Denmark, France, Germany, Iceland, Luxemburg, Netherlands, Norway, and Slovakia. According to Novo Nordisk, a quality control conducted by the Company showed that a small percentage (0.14%) of the products in these batches do not meet the specifications for insulin strength, which may lead to the patient's blood sugar level becoming higher or lower than expected. Novo Nordisk reported that three batches of NovoMix30 Penfill are being recalled in Ireland and UK and stated that other countries in the EU might have also received the affected batches through parallel distribution. The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/fee1_NVO] -- Cynosure, Inc. Research Report On October 29, 2013, Cynosure, Inc. (Cynosure) released its Q3 2013 results. Cynosure registered revenues of $60.7 million in Q3 2013, up 63.7% YoY. The Company posted a net loss of $1.3 million in Q3 2013, compared to a net income of $3.4 million in Q3 2012. Cynosure reported diluted loss per share of $0.06 in Q3 2013, compared to diluted earnings per share of $0.25 in Q3 2012. Michael Davin, Cynosure's Chairman, CEO, and President, said, "Our first full quarter as a combined company demonstrated the complementary nature of the Cynosure and Palomar businesses, the breadth of our laser- and light-based aesthetic product lines and our strong global distribution capabilities." Davin continued, "Primarily related to the acquisition of Palomar, third-quarter 2013 laser revenues were up 62% to $50.1 million compared with $31.0 million for the same period of 2012, reflecting growth in both North American and international distribution channels." The Full Research Report on Cynosure, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/6e59_CYNO] -- Hospira Inc. Research Report On October 23, 2013, Hospira Inc. (Hospira) announced the launch of the Q core Sapphire infusion system in the US, representing a major step in the advancement of the Company's global device strategy. Dr. Boaz Eitan, CEO of Q Core Medical, commented, "We are proud to make this important step forward together with Hospira and launch our Sapphire system in the US market." Eitan added, "This is yet another successful stage in the international cooperation between the companies, and we believe that the combination of our technology with Hospira's excellent customer support and in-depth experience in the U.S. market will begin a new era in infusion solutions for our customers." The Full Research Report on Hospira Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/1f43_HSP] -- Celsion Corp. Research Report On October 24, 2013, Celsion Corp. (Celsion) announced that the latest overall survival data from its post-hoc analysis of results from the Phase III HEAT Study of ThermoDox supports continued clinical development through a prospective pivotal Phase III Study, subject to regulatory review and agreement. Michael H. Tardugno, Celsion's President and CEO, stated, "Equally important is that the data supporting our continued development program has been carefully reviewed by our HEAT Study principal investigators, international liver cancer experts, former FDA reviewers and independent statisticians." Tardugno continued, "We will present these findings in detail to the U.S Food and Drug Administration during the fourth quarter and we will work with the Agency on the best path forward in a pivotal study." The Full Research Report on Celsion Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e8ef_CLSN] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Community Programs, Product Recalls, Quarterly Reports, Product Launches, and Study Results - Research Report on DaVita, Novo
Press spacebar to pause and continue. Press esc to stop.